Located at the St. Leonards North Shore Hospital campus where GenesisCare are developing comprehensive, integrated cancer services. Currently, Theranostics treatments are provided at North Shore Radiology and Nuclear Medicine in North Shore Private Hospital but will soon be moving to a dedicated theranostics facility in the new North Shore Health Hub (Dexus) building on the North Shore hospital campus, due to open in mid-2021.
Our theranostics service is an evolving approach to cancer management, combining diagnostic imaging and radionuclide therapy. Most evidence to date is in metastatic castrate resistant prostate cancer and advanced neuroendocrine tumours (NETs).
Our team and expertise
Since 2016, GenesisCare has administered over 1000 treatment doses of 177Lutetium to more than 300 cancer patients in Australia. Patients have access to advanced theranostic treatment options using the latest technology, delivered by our highly experienced Nuclear Medicine team. Our clinical team are committed to the use of the latest technology and treatments.
What is involved?
Once a request for theranostics therapy is received, an initial consultation will be arranged for you to assess your suitability for treatment and to ensure that the therapy is provided appropriately and safely for each individual patient. The theranostics clinical research team will also assess whether you are eligible for any of the clinical trials that are currently taking place.
Treatments are performed as an outpatient and involve intravenous or oral hydration prior to, and following treatment administration, generally a period of approximately 4 hours at the facility will be required. Hospital admission is not required as the treatment is usually well tolerated.
Treatments are performed 6-8 weeks apart and 3-4 treatment cycles (up to 6) are required depending on treatment response and tolerability.